vedroprevir
Small moleculeexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01271790)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
A3EZI9 inhibitor
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3csc(NC(C)C)n3)nc3c(Cl)c(OCCN4CCOCC4)ccc23)CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)C(=O)O- Mol. weight
- 910.53 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2013174 ↗
Also known as
- gs-9451
- gs-9451
- gs-9451
- gs-9451
- vedroprevir
- vedroprevir
- vedroprevir
- vedroprevir
- vedroprevir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02226549 | Phase 2 | Jul 1, 2014 | Gilead Sciences |
| NCT01805882 | Phase 2 | Jan 1, 2013 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT01434498 | Phase 2 | Sep 1, 2011 | Gilead Sciences |
| NCT01435226 | Phase 2 | Sep 1, 2011 | Gilead Sciences |
| NCT01384383 | Phase 2 | Aug 1, 2011 | Gilead Sciences |
| NCT01371578 | Phase 2 | Jul 1, 2011 | Gilead Sciences |
| NCT01356160 | Phase 2 | Jul 1, 2011 | Gilead Sciences |
| NCT01353248 | Phase 2 | May 1, 2011 | Gilead Sciences |
| NCT01271790 | Phase 2 | Oct 1, 2010 | Gilead Sciences |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 8 | 8 | 1 | 2010 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1